Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page revision tag was updated from v3.6.2 to v3.6.3, indicating a minor update to the page. No substantive study content appears to be changed.
    Difference
    0.1%
    Check dated 2026-07-04T01:07:54.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.0 to v3.6.2, signaling a small maintenance update to the ClinicalTrials.gov study page rather than a substantive content change.
    Difference
    0.1%
    Check dated 2026-06-26T23:15:40.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page now presents new guidance/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and a 'No longer looking for participants' notice. The Intervention/Treatment heading has been updated and the older 'Intervention / Treatment' label removed, alongside a new revision indicator 'Revision: v3.6.0' replacing the previous version.
    Difference
    0.4%
    Check dated 2026-06-12T14:08:30.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The page's revision tag has been updated from v3.5.4 to v3.5.5, representing a new build of the ClinicalTrials.gov page. It indicates an update to the site software rather than changes to the study information presented on the page.
    Difference
    0.1%
    Check dated 2026-06-05T10:07:11.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page adds a new site revision tag for v3.5.4 and removes the previous v3.5.3 label, signaling a small platform update in the release notes area rather than changes to the study information.
    Difference
    0.1%
    Check dated 2026-05-15T02:16:05.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page now displays a new revision tag (v3.5.3), replacing the previous v3.5.2, indicating a release update to the page's content management without altering study data. No study details or eligibility criteria appear to be changed.
    Difference
    0.1%
    Check dated 2026-04-30T18:41:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.